Chromogranin A—Biological Function and Clinical Utility in Neuro Endocrine Tumor Disease
- 9 March 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 17 (9), 2427-2443
- https://doi.org/10.1245/s10434-010-1006-3
Abstract
Neuroendocrine tumors (NETs) are a form of cancer that differ from other neoplasia in that they synthesize, store, and secrete peptides, e.g., chromogranin A (CgA) and amines. A critical issue is late diagnosis due to failure to identify symptoms or to establish the biochemical diagnosis. We review here the utility of CgA measurement in NETs and describe its biological role and the clinical value of its measurement. Literature review and analysis of the utility of plasma/serum CgA measurements in NETs and other diseases. CgA is a member of the chromogranin family; its transcription and peptide processing are well characterized, but its precise function remains unknown. Levels are detectable in the circulation but vary substantially (approximately 25%) depending on which assay is used. Serum and plasma measurements are concordant. CgA is elevated in approximately 90% of gut NETs and correlates with tumor burden and recurrence. Highest values are noted in ileal NETs and gastrointestinal NETs associated with multiple endocrine neoplasia type 1. Both functioning and nonfunctioning pancreatic NETs have elevated values. CgA is more frequently elevated in well-differentiated tumors compared to poorly differentiated NETs. Effective treatment is often associated with decrease in CgA levels. Proton pump inhibitors falsely increase CgA, but levels normalize with therapy cessation. CgA is currently the best available biomarker for the diagnosis of NETs. It is critical to establish diagnosis and has some utility in predicting disease recurrence, outcome, and efficacy of therapy. Measurement of plasma CgA is mandatory for the effective diagnosis and management of NET disease.Keywords
This publication has 139 references indexed in Scilit:
- Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancerArchives of Gerontology and Geriatrics, 2009
- Chromogranin A as an Alternative to 5-Hydroxyindoleacetic Acid in the Evaluation of Symptoms during Treatment of Patients with Neuroendocrine TumorsNeuroendocrinology, 2008
- Priorities for Improving the Management of Gastroenteropancreatic Neuroendocrine TumorsJNCI Journal of the National Cancer Institute, 2008
- The trans-Golgi Proteins SCLIP and SCG10 Interact with Chromogranin A To Regulate Neuroendocrine SecretionBiochemistry, 2008
- Gastroenteropancreatic neuroendocrine tumoursThe Lancet Oncology, 2008
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tractWorld Journal of Surgery, 1992
- The role of interferons in the management of carcinoid tumoursBritish Journal of Haematology, 1991
- Bioactivity of synthetic human pancreastatin on exocrine pancreasBiochemical and Biophysical Research Communications, 1988
- Chromogranin C: A Third Component of the Acidic Proteins in Chromaffin GranulesJournal of Neurochemistry, 1986